Invesco Ltd. decreased its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 3.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,649,585 shares of the biopharmaceutical company's stock after selling 58,864 shares during the period. Invesco Ltd. owned approximately 1.25% of Dynavax Technologies worth $21,065,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in DVAX. E Fund Management Co. Ltd. increased its holdings in Dynavax Technologies by 4.6% during the 4th quarter. E Fund Management Co. Ltd. now owns 17,627 shares of the biopharmaceutical company's stock worth $225,000 after purchasing an additional 771 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Dynavax Technologies by 19.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock worth $83,000 after buying an additional 1,076 shares during the period. Sanctuary Advisors LLC grew its holdings in shares of Dynavax Technologies by 6.3% during the fourth quarter. Sanctuary Advisors LLC now owns 18,836 shares of the biopharmaceutical company's stock worth $245,000 after buying an additional 1,109 shares in the last quarter. Russell Investments Group Ltd. raised its position in Dynavax Technologies by 96.5% in the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 1,169 shares during the last quarter. Finally, GAMMA Investing LLC boosted its position in Dynavax Technologies by 55.1% during the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company's stock worth $52,000 after acquiring an additional 1,457 shares during the last quarter. 96.96% of the stock is currently owned by institutional investors and hedge funds.
Dynavax Technologies Stock Performance
Dynavax Technologies stock traded up $0.23 during midday trading on Thursday, reaching $11.00. 238,589 shares of the company's stock were exchanged, compared to its average volume of 2,340,422. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The stock's 50-day simple moving average is $12.86 and its 200 day simple moving average is $12.54. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of 61.12 and a beta of 1.26. Dynavax Technologies Co. has a 52 week low of $9.74 and a 52 week high of $14.63.
Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, hitting analysts' consensus estimates of $0.05. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The business had revenue of $72.03 million for the quarter, compared to analyst estimates of $72.70 million. On average, analysts expect that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several brokerages have commented on DVAX. HC Wainwright reissued a "buy" rating and set a $31.00 price target on shares of Dynavax Technologies in a research report on Friday, February 21st. William Blair restated an "outperform" rating on shares of Dynavax Technologies in a research note on Friday, February 21st. StockNews.com upgraded Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Monday, February 24th. Finally, The Goldman Sachs Group decreased their target price on shares of Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating for the company in a research note on Thursday, April 17th.
Check Out Our Latest Research Report on Dynavax Technologies
Dynavax Technologies Company Profile
(
Free Report)
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
See Also
Before you consider Dynavax Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.
While Dynavax Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
